Market revenue in 2022 | USD 658.7 million |
Market revenue in 2030 | USD 1,364.0 million |
Growth rate | 9.5% (CAGR from 2022 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Enzymes |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Kits & Reagents, Enzymes |
Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Agilent Technologies Inc, Qiagen NV, New England Biolabs, Merck KGaA, Roche Holding AG ADR, Bio-Rad Laboratories Inc, Takara Bio Inc, LGC Group, Bausch Health Companies Inc, Promega |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular biology enzymes, reagents and kits market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 67.5% in 2022. Horizon Databook has segmented the UK molecular biology enzymes, reagents and kits market based on kits & reagents, enzymes covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing collaborations between key market players and research institutes coupled with rising research funding in the country is anticipated to contribute to the market growth. Recently, in May 2020, Genomics England in collaboration with Genetics of Mortality in Critical Care launched an initiative to sequence 35,000 COVID-19 patient genomes.
This initiative is aimed at understanding the impact of genetic makeup on reaction to the virus. Such initiatives are anticipated to increase the demand for molecular biology enzymes, kits, and reagents in the country.
In addition, in January 2020, Genomics England partnered with Illumina, Inc. on a whole genome sequencing project. Through this partnership, samples from NHS patients with known rare diseases and cancer types are eligible for WGS to aid in development of diagnostics and improve treatment regime.
Horizon Databook provides a detailed overview of country-level data and insights on the UK molecular biology enzymes, reagents and kits market , including forecasts for subscribers. This country databook contains high-level insights into UK molecular biology enzymes, reagents and kits market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account